Changes to sialylated glycans in cancer include an upregulation of the Sialyl Lewis antigens (sLeA and sLeX), an increase in the truncated O-glycan sialyl-Tn (STn) and an increase in the sialylated ganglioside GM2 [52] (Figure 1). Here, EEF1A2 is linked to cancer.